[ad_1]
In this context, Dr. Myron Cohen, a virologist at the University of North Carolina who provides advice to the government on Covid-19 treatments, said: "These types of results tell us when to benefit.".
He explained that tests on animals indicate that antibody drugs work best when given early in the infection, to reduce the amount of virus.
He added that once someone becomes seriously ill, these medications may not help. "But it’s too early to tell if this is the case".
He noted that tests on animals revealed that antibody drugs work best when given early in infection to reduce the amount of virus.
And doctors already know that time can be important when it comes to treatments for Corona.
Studies show that "Dexamethasone" Other stimulants can reduce the risk of death when given to seriously ill patients to suppress an overactive immune system, but they can be harmful to those with mild illness.
Intervals "Regeneron" She plans to share Friday’s advice from independent observers, with the US Food and Drug Administration and the leaders of a separate UK study, which is also testing her drug in hospitalized patients.
“>
On Friday, the pharmaceutical company Regeneron announced that independent observers had recommended suspending the registration of seriously ill people (those who require intensive oxygen therapy or ventilators), due to “a possible safety problem and an inadequate balance of risks and benefits.”
Observers said the study could continue to test the two-antibody drug combination in hospitalized patients who need little or no additional oxygen.
Other studies continue in people with mild or moderate symptoms, according to the Associated Press.
Of note, antibodies are proteins that the body produces when an infection occurs and attaches itself to the virus and helps to eliminate it. However, the most effective ones can take several weeks to form.
Experimental drugs aim to help with this right away, by providing concentrated copies of one or two antibodies, which work best against the Corona virus in laboratory and animal tests.
And in early October, a different group of observers recommended temporarily suspending registration in a study by the US National Institutes of Health to test the antibody drug “Eli Lilly,” in order to investigate a possible problem with safety for patients in the hospital.
On Monday, the National Institutes of Health said “no safety concerns have been verified,” but that they stopped the study because the drug does not appear to work in this situation.
“These kinds of results inform us about the timing of the benefit,” said Dr. Myron Cohen, a virologist at the University of North Carolina who advises the government on treatments for Covid-19.
He explained that tests on animals indicate that antibody drugs work best when given early in the infection, to reduce the amount of virus.
He added that once someone is seriously ill, these medications may not help, “but it is too early to know if this is the case.”
He noted that tests on animals revealed that antibody drugs work best when given early in the infection to reduce the amount of virus.
And doctors already know that timing can be important when it comes to treatments for Corona.
Studies indicate that “dexamethasone” and other stimulants may reduce the risk of death when administered to seriously ill patients, to suppress an overactive immune system, but may be harmful for those with mild illness.
Regeneron said he intends to share Friday’s advice from independent observers, with the US Food and Drug Administration and the leaders of an independent study in the UK, also testing his drug in hospitalized patients.
[ad_2]
